Filing Flows › Myriad Genetics (MYGN) › How it makes money
How Myriad Genetics (MYGN) makes money
Myriad Genetics (MYGN) made $203M of revenue in the third quarter 2026 (Q3 2026), -1% from a year earlier. Cancer Care Continuum brought in $124M (61%); Mental Health brought in $39.5M (19%); Prenatal Health brought in $39.3M (19%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Cancer Care Continuum | $124M | 61.1% | +9% | +1% |
| Mental Health | $39.5M | 19.5% | +7% | +2% |
| Prenatal Health | $39.3M | 19.4% | -1% | -12% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $203M | 100.0% |
| Income tax | $300K | 0.1% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $203M | -2% |
| Q2 2026 | $191M | -10% |
| Q1 2026 | $200M | +2% |
| Q4 2025 | $210M | -0.4% |
| Q3 2025 | $206M | -4% |
| Q2 2025 | $213M | +0.8% |
| Q1 2025 | $196M | -3% |
From Myriad Genetics' 10-Q filed Nov 6, 2026 (on EDGAR).
Questions
How does Myriad Genetics make money?
Myriad Genetics (MYGN) made $203M of revenue in the third quarter 2026 (Q3 2026), -1% from a year earlier. Cancer Care Continuum brought in $124M (61%); Mental Health brought in $39.5M (19%); Prenatal Health brought in $39.3M (19%).
What is Myriad Genetics' biggest business?
Cancer Care Continuum: $124M in the third quarter 2026, 61% of revenue, +1% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.